Category: ACN Newswire

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

TORONTO, ON, Sep 17, 2024 – (ACN Newswire via SeaPRwire.com) – Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities

More

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

SINGAPORE, Sept 17, 2024 – (ACN Newswire via SeaPRwire.com) – Cordlife Group Limited (“Cordlife” or the “Company” and together with its subsidiaries, the “Group”), which has been approved to resume cord blood banking activities in Singapore in a controlled manner, today

More